RecruitingNCT07377682
Real-world Clinical Response to Trazodone in Italy, Poland, and Romania
Observational Prospective Study in Patients With Major Depressive Disorder and Mild Cognition Impairment Treated With Trazodone in a Real-world Setting (TRACOMDD)
Sponsor
Aziende Chimiche Riunite Angelini Francesco S.p.A
Enrollment
120 participants
Start Date
Dec 15, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
TRACOMDD study is a study with the intention to describe the real-world use of trazodone and the clinical response in a sub-group of patients affected by Major Depressive Disorder and Mild Cognitive impairment, by collecting data from standard clinical practice in Italy, Poland, and Romania
Eligibility
Min Age: 55 Years
Inclusion Criteria6
- Patients aged 55 or older.
- Patients who meet the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for MDD diagnosis.
- Patients experiencing a current major depressive episode of at least moderate severity, defined by a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥20 at enrolment.
- Patients with a diagnosis of MCI (also referred to as "mild neurocognitive disorder") according to the DSM-5 criteria.
- Patients who start treatment with trazodone hydrochloride (prolonged release) with starting dosage according to SmPC at enrolment visit (or at latest within one week).
- Patients legally capable of giving their written consent to participate in the study (including personal data processing) and willing to comply with all study procedures as per clinical judgement.
Exclusion Criteria7
- Patients who meet any of the contraindications to the administration of trazodone according to the approved local SmPC.
- Known hypersensitivity or allergy to the active ingredient and/or to any component of the study medication.
- Concomitant treatment with other antidepressant drugs, mood stabilizers, antipsychotics, and/or proved resistance to trazodone monotherapy.
- Patients with current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, severe personality disorder, mental retardation, organic mental disorders, or mental disorders due to a general medical condition.
- Patients with previous or current history of any neurological condition that, in the opinion of the Investigator, might compromise participation in the study.
- Patients participating in any interventional study in the 30 days prior to the enrolment visit.
- Patients with ongoing pregnancy or breast-feeding at enrolment visit.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07377682
Related Trials
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT0679339767 locations
IMST for Dementia Risk Reduction
NCT073497061 location
TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children
NCT074787961 location
Behavioral Health Collaborative Care Model in an ICU Recovery Clinic
NCT073725861 location
Behavioral Health Collaborative Care Model in Post-ICU Clinic Family Pilot
NCT073907861 location